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Background: How best to prioritise COVID-19 vaccination within and between countries has been a 
public health and an ethical challenge for decision-makers globally. We systematically reviewed 
epidemiological and economic modelling evidence on population priority groups to minimise 
COVID-19 mortality, transmission and morbidity outcomes. 
 
Methods: We searched the National Institute of Health iSearch COVID-19 Portfolio (a database of 
peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research and the 
National Bureau of Economic Research for mathematical modelling studies evaluating the impact of 
prioritising COVID-19 vaccination to population target groups. We narratively synthesised the main 
study conclusions on prioritisation and the conditions under which the conclusions changed.  
 
Findings:  The search identified 1820 studies. 36 studies met the inclusion criteria and were 
narratively synthesised. 83% of studies described outcomes in high-income countries. We found that 
for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal 
strategy and for countries seeking to minimise cases the young were prioritised. There were several 
exceptions to the main conclusion, notably reductions in deaths could be increased, if groups at high 
risk of both transmission and death could be further identified. Findings were also sensitive to the 
level of vaccine coverage.   
 
Interpretation: The evidence supports WHO SAGE recommendations on COVID-19 vaccine 
prioritisation. There is however an evidence gap on optimal prioritisation for low- and middle- income 
countries, studies that included an economic evaluation, and studies that explore prioritisation 
strategies if the aim is to reduce overall health burden including morbidity. 
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As of June 2021, over 1.5 billion vaccine doses have been administered, but vaccines are still 
in limited supply in the short to medium term in the vast majority of countries. [1] The 
question of which groups should be prioritised for vaccination within countries and between 
them has continued to present both a public health and an ethical challenge to decision 
makers. [2] 
 
The World Health Organisation (WHO) Strategic Advisory Group of Experts on 
Immunization (SAGE) working group on COVID-19 vaccines has provided guidance to 
countries on the prioritisation of groups for vaccination while supply is limited. The 
guidance, based on the WHO SAGE values framework for the allocation and prioritization of 
COVID-19 vaccines, seeks to ensure equitable protection of human health across the globe, 
and in particular, among those experiencing the greatest risk and burden of COVID-19. [2, 3]  
 
Epidemiological and economic models can provide an assessment of the potential health and 
broader societal impact of different prioritisation policies, and identify the optimal groups to 
prioritise for vaccination, given different public health objectives and scenarios. These results 
can be considered alongside other decision criteria to allocate vaccines both globally and 
within countries faced with a limited supply.  
 
 
There was only a limit set of modelling results available to inform SAGE decision making at 
the end of 2020 (Figure 1), but in early 2021 the evidence base greatly expanded. The model 
results available at that time were largely limited to high-income and high-transmission 
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settings such as the United States of America (USA) and United Kingdom (UK). Models 
specifically addressing low- and middle-income countries as well as low-transmission 
settings were not available.  
 
We aimed to systematically review the epidemiological and economic modelling literature on 
population groups to prioritise for COVID-19 vaccination to minimise COVID-19 mortality, 
transmission and morbidity outcomes, in order to inform prioritisation policy at both the 
global and national levels. Our study is structured around the policy questions that SAGE 
considered in 2020. In summary, these questions examined exploring optimal allocation by 
age groups, occupational groups, groups with comorbidities and groups at higher risk of 





Search strategy and selection criteria 
 
The systematic literature review was performed in line with PRISMA guidelines (Figure 2). 
[4] We searched the National Institute of Health (NIH) iSearch COVID-19 Portfolio on the 
3rd of March 2021 (a database which sources peer-reviewed articles from Pubmed and 
preprints from arXiv, bioRxiv, ChemRxiv, medRxiv, Preprints.org, Qeios, Research Square, 
and SSRN). We searched Econlit on the 3rd of March 2021, using the advanced filters to 
include studies published between 2020 and 2021. To search these databases, we used a 
Boolean ra eg  o combine ke ord  ch a  model* , acc* , econom* , co  and 
COVID-19 . We con ac ed he Cen re for Economic Polic  Re earch in the United 
Kingdom and the National Bureau of Economic Research in the United States and received 
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their full datasets of studies on the economics of COVID-19. (See Table S1 for the full search 
strategy and further details).  
 
We included English language studies that used mathematical modelling to assess the impact 
of prioritising population target groups (either within or between countries) for COVID-19 
vaccination on mortality, health (e.g. cases, quality adjusted life years), health care (e.g. 
hospitalisations) and/or economic (e.g. costs and cost-effectiveness) outcomes. We excluded 
studies which did not use a mathematical model to project the impact of COVID-19 
vaccination, where none of the parameters were determined by empirical data (e.g. 
theoretical, non-empirical models), or which modelled vaccination outcomes within a clinical 
trial or a within-country small local setting, such as a care home, rather than nation or district 
wide allocation. 
 
Two researchers independently screened titles and abstracts during the first round of 
screening. During the second round, three researchers independently screened titles/abstracts 
and full text articles. All studies were screened by at least two reviewers; where there were 
disagreements about inclusion these were resolved in discussion with a fourth researcher. 
Three groups of two researchers each independently extracted the data from the included 
studies, with at least two groups reviewing each study. Discordant entries between the sets of 
extraction sheets were resolved by discussion between the groups.  
Data were recorded in Microsoft Excel files summarising the policy objectives, outcomes, 
characteristics of the studies, the study conclusions and the conditions under which the 
conclusions changed i.e. sensitivity analyses (see supplementary materials to download the 
full extraction sheet).  
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Studies explored the optimal prioritisation strategy based on different policy objectives/ 
outcomes (deaths, cases etc.). We therefore extracted data and organised our results tables by 
the objective used. Some studies used two objectives to inform prioritisation (for example 
cases and deaths). In this instance we extracted and synthesised both sets of results. A full list 
of objectives of the included studies can be found in Table 1.  
 
We referred to he Economic and Social Re earch Co ncil  g idance on he cond c  of 
narrative synthesis to aid data synthesis. [5] We therefore organised and grouped the textual 
results of the studies so that we could identify patterns within and between them.  Synthesis 
was organised by the outcomes being explored.  Due to wide variation between the studies in 
age group boundaries and other group classifications, extracted data from the study 
conclusions on vaccination priority groups were re-classified into broader population 
categories to aid synthesis. The population group categories considered were 
children/adolescents (ages 0-18), young adults (ages 19-40), middle-aged adults (ages 41-64), 
seniors (65+), groups with comorbidities, high social contact groups, essential workers, 
health workers and geographic regions.   
 
Studies had different combinations of comparators, so we present results specifying the full 
range of comparator populations assessed. Study setting was categorised as High-Income 
(HIC), Upper Middle-Income (UMIC), Lower-Middle Income (LMIC), Low Income (LIC), 
multi-region or not specified, using World Bank classifications for 2021. [6]  We extracted 
the modelling methods used, and reviewed assumptions and model structure in detail for the 
studies that did not align with the majority of conclusions to identify if this was based on an 
exceptional method (referred to as e cep ion ). We also report where sensitivity analyses 
generated results that were contrary to main findings of the study. 
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Our database search returned 2279 studies. After the removal of 459 duplicates, 1820 records 
were included in the title and abstract screening. After title and abstract screening, 55 studies 
remained for full text screening. After assessing the full text of the 55 studies for eligibility, 
36 studies were included in the systematic review (see full extraction sheet Excel file in the 
supplementary materials and PRISMA flow diagram in Figure 2). 
 
Study characteristics are summarised in Table 1. All the reviewed studies used models that 
captured transmission between individuals, with deterministic compartmental models being 
most common (23/36). However, agent-based models (5/36), stochastic compartmental 
models (4/36), a delay differential equation model (1/36), and a linear model (1/36) were also 
used. Studies most commonly used a SEIR (Susceptible, Exposed, Infected, Recovered) 
(11/36) or Expanded SEIR (15/36) natural history.  
 
Most of them were set in a HIC (26/36); there were few single-country UMIC (1/36) and 
LMIC (3/36) studies. There were no single-country studies in a LIC setting. Only a few 
(4/36) looked at more than one country and two did not explicitly state the study setting. 
Most studies explored multiple policy objectives/outcomes regarding prioritisation: 28/36 
investigated strategies to minimise deaths, 23/36 investigated minimisation of cases, 11/36 
hospitalisations, 1/36 Quality Adjusted Life Years (QALYs), 1/36 Disability Adjusted Life 
Years (DALYs) and 3/36 Years of Life Lost (YLLs). Only 2/36 considered economic 
outcomes, such as financial or economic costs, in relation to prioritisation.  
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Prioritisation to minimise deaths  
 
Table 2 summarises the study conclusions highlighting the priority group and all the 
comparators included in each study (see methods section for how we defined population 
group categories). Most studies included seniors in the priority group. Thirteen studies 
recommended that seniors should be prioritised for vaccination to minimise deaths. [7] [8] [9] 
[10] [11] [12] [13] [14] [15] [16] [17] [18] [19] One study recommended prioritising seniors 
with comorbidities [20], and six studies recommended vaccinating seniors at the same time as 
another priority group (middle-aged adults, the highest social contact group, young and 
middle-aged adults who are in high contact with them, young adults with partial vaccine 
dose, and health workers). [21] [22] [23] [24] [25] [26]   
 
Ten studies did not find that prioritising the groups at highest risk of mortality (seniors or 
people living with comorbidities) minimised deaths. [27] [28] [29] [30] [31] [32] [33] [24] [23] 
[34] These e cep ional  studies instead found that prioritising groups with a higher risk of 
infection would lead to fewer deaths; in other words, that the indirect protection from lower 
transmission outweighs the benefits from direct protection from vaccines for those at the 
highest risk of mortality. The group at high risk of infection were defined as those with: 
higher contact rates e.g. synthetic population with 3-10 times the average number of contacts 
of the age group 30-39 [23]; individuals with an expansive social network [31] [32]; and 
individuals with essential worker status. [27] [28] In addition, two studies defined young 
adults as the group with the highest social interactions and therefore at higher risk of 
infection. [29] [33] One study examined vaccination of individuals that had high levels of 
interaction with seniors. [24] 
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One of the ten exceptional studies concluded that the non-vulnerable group should be 
prioritised for vaccination compared to the group with comorbidities. [30] In this study the 
authors state they assumed ha  he ime req ired o accina e he lnerable gro p i  
identical to that of the much larger non- lnerable gro p , e en ho gh he non-vulnerable 
group was much larger. Finally, one study recommended prioritising vaccination through the 
use of serological testing to achieve the greatest reduction in COVID-19 related deaths. [35] 
 
 
Prioritisation to minimise COVID-19 cases 
 
Table 3 summarises the study conclusions. The largest proportion of the selected studies 
(N=23) investigated optimal vaccine prioritisation strategies to minimise COVID-19 cases. 
Of these, six studies recommended young and middle aged adults, [10] [16] [12] [22] [15] [17] 
one young adults, [33] and two young adults and children. [21] [26] One study recommended 
young people at the same time as another priority group (seniors at full vaccine dose and 
young adults at partial dose). [25]  
 
Seven studies recommended vaccination prioritisation based on social or occupational 
interactions compared to age group prioritisation. [28] [27] [31] [32] [36] [14] [37] Of these, 
three studies recommended prioritising essential workers to minimise cases  [28] [27] [14] 
and four studies recommended prioritising high social contact adults compared to other age 
groups. [31] [32] [37] [36] 
 
Two studies recommended prioritising vaccination using serological testing to prioritise 
antibody-negative individuals compared to not using serological testing, [35] [38] and a 
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further study recommended that the geographic area with lower disease burden should be 
prioritised for vaccination compared to the geographic area with high disease burden. [39] 
 
 
There were a few studies concluding differently to the majority recommendations on 
minimising cases. Three studies found that scenarios targeting seniors [13] [18] [25] led to the 
highest reduction in cases. However, two of those studies did not have a comparator that 
modelled those strategies comparted to more socially interactive populations. [18] [25] 
Chhetri et al found very small differences between scenarios, and the conclusion was not 
reported in the results section. [13] 
 
Prioritising other outcomes 
 
Studies investigating strategies to minimise hospitalisations from COVID-19 tended to reach 
similar conclusions to studies investigating deaths (N=11).  Seven studies recommended 
prioritising senior adults [8] [15] [16] [41] [37], senior and middle-aged adults [21] or seniors 
and the high social contact group [23] for vaccination compared to other age and occupational 
groups. 4 studies concluded differently from the majority of the hospitalisation outcome 
studies. [31] [32] [38] [40] Two recommended prioritising the high social contact group 
compared to prioritising senior adults. [31] [32] One study recommended prioritising 
vaccination by serological testing compared to no serological testing. [38] One study 
recommended giving equal priority to all age and risk groups compared to a targeted age-
based prioritisation. [40] 
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A few studies investigated the optimal vaccination strategy when maximising QALYs, 
DALYs or YLLs. One study modelled the vaccination prioritisation strategy to minimise 
QALY losses. [11] The authors concluded that the most effective strategy to minimise QALY 
losses is to prioritise senior adults for vaccination compared to other age groups, groups with 
comorbidities and no group prioritisation. Three studies investigated within-country vaccine 
prioritisation strategies for minimising YLLs. [12] [28] [22]  Two studies recommended 
prioritising seniors for vaccination to minimise YLLs [12][28] and the other recommended 
prioritising middle aged adults and seniors.  [22] One study modelled the impact of COVID-
19 vaccination on DALYs. [19] The authors found that the amount of DALYs averted under 
a base vaccination strategy which prioritised seniors was stable to a scenario where everyone 
over 15 years old is vaccinated. [19] 
 
One study considered the cost-effectiveness of COVID-19 vaccination. [19] The authors 
found that the strategy of prioritising seniors for vaccination was similarly cost-effective to 
vaccinating all individuals over 15 years old. [19] 
One study investigated prioritisation strategies for optimising the incremental net monetary 
benefit (iNMB) of vaccination, i.e. the net economic gain from vaccination including both 
costs saved and monetised health gains. [40]  The authors concluded that giving equal priority 
to all age and risk groups was most optimal compared to prioritising seniors, high risk 
individuals, and both seniors and high risk individuals when vaccine effectiveness was only 
moderate (40%) and coverage was low (20%). Conversely, when vaccine effectiveness was 
high (80%) and coverage was moderate (50%), vaccinating high risk individuals resulted in 
the highest iNMB.  
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Prioritisation by setting 
 
Three of the included articles were single-country studies modelling LMIC settings. [14] [17] 
[19]   One study modelled an UMIC setting. [33] These studies reached the same conclusions 
as the HIC studies apart from one: those minimising deaths recommended prioritising 
seniors, while those minimising cases recommended prioritising high transmission groups. 
The exception was one study from Thailand on minimising cases which recommended 
prioritising high transmission groups to minimise deaths. [33]  
 
Additionally, there were three multi-country studies which modelled LMIC settings [8] [9]  
[12] and one modelling an UMIC setting. [23]  The conclusions for these studies were in line 
with the majority conclusions for deaths and cases (except for one study which recommended 
prioritising both the high social contact group and seniors to minimise deaths). [23] See Table 
S5 for a summary of the studies modelling UMIC and LMIC settings.  
 
One study also considered prioritisation between countries, in addition to within countries. 
This study made recommendations on global vaccine allocation strategies to optimise 
different health objectives. [9]  The authors concluded that the strategy to minimise deaths 
was to allocate doses equitably across all income settings relative to population size, and then 
to prioritise vaccination of seniors within countries. This performed better than allocating 
vaccines to countries based on their respective senior population sizes, giving preferential 
allocation to HICs, giving preferential allocation to LICs and LMICs, or allocating doses in 
proportion to population plus providing a set number of extra doses to HIC and UMICs. [9] 
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When YLLs were used as an optimisation outcome measure, LMIC settings received the 
most doses.   
 
Factors that influence prioritisation strategy 
 
35 out of 36 (97%) studies included a sensitivity analysis. Of these, 14 studies reported a 
sensitivity analysis that led to a potential change in the recommended prioritisation strategy.  
Whilst there were a wide range of parameters tested in the uncertainty analysis there were 
only a few that consistently drove a change in prioritisation. The most common parameters 
that influenced prioritisation all related to vaccine coverage (level of vaccine supply, vaccine 
coverage, and speed of vaccine rollout).  
 
Six studies reported that the trade-off between direct and indirect protection is sensitive to the 
proportion of people vaccinated.  [12] [9] [21] [22] [15] [32] These papers stated that when 
vaccine supply is very low vaccination has a minimal impact on interrupting transmission, so 
more deaths can be prevented to vaccinate groups at risk of severe disease (e.g., key workers, 
seniors and clinical risk groups). However, as supply increases, this opens up the possibility 
of interrupting transmission, which can change prioritisation to the young or those with many 
contacts. If there is very high vaccine supply, seniors are again favoured for prioritisation if 
aiming to reduce deaths, as there is sufficient coverage to achieve both direct protection of 
the most vulnerable and indirect protection from key transmitters.  
 
Several studies tested different values of vaccine efficacy, with most reporting before full 
results of vaccine trials became available starting in late 2020. Generally, variations in 
vaccine efficacy did not appear to change prioritisation unless efficacy was significantly 
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lower in older rather than younger populations. However, a number of studies assumed that 
vaccines had similar levels of efficacy against severe disease, infection or transmission. 
Where vaccines were more efficacious against severe disease strategies, the priority was to 





We find that for countries seeking to minimise deaths, the current evidence base supports 
prioritising vaccination of senior adults (65+) as the optimal strategy, unless there are 
exceptional cases where specific non-age-related high-risk groups or very highly networked 
individuals can be identified and prioritised.  The difference in deaths averted can be large 
between depending on the strategies, for example in one study, a symptom-blocking vaccine 
with 50% uptake prioritising seniors and high-risk groups averted 17000 more deaths than an 
unprioritized campaign. [20] For countries seeking to minimise cases, the evidence supports 
prioritising young age groups and essential workers. The evidence base examining the 
optimal strategy to improve health in general is too limited to draw any firm conclusions.  
 
While in principle prioritising highly socially connected groups may be optimal to reduce 
mortality, it could prove difficult in practice to identify these groups, especially when their 
definition and identification are only vaguely defined. [31] [32] [24] [23] Chen et al. suggest 
those population groups could be identified through contact tracing, although recognising the 
limitations of such an approach in resource constrained settings. [23] Santini recommends 
prioritising younger people with many connections to vulnerable people. [24]  Buckner et al. 
find that prioritising essential workers (based on occupation) could lead to fewer deaths in the 
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context of strong non-pharmaceutical interventions. [28]  As no studies included the 
feasibility and costs of identifying and delivering vaccines to highly-connected groups, it is 
unclear whether prioritisation to groups that are not age or occupation-based is possible or 
cost-effective. 
 
Luangasanatip et al. examined how vaccines may be prioritised in a low-incidence setting 
(Thailand). [33] finding that prioritising younger age groups would lead to greater reductions 
in deaths. However, this was the only study set in a low incidence setting, so more research 
may be required to validate this finding across settings and modelling approaches. The small 
number of studies set in low- and middle-income countries, and the lack of evidence on the 
cost-effectiveness of reaching different population also limits our findings in resource 
constrained settings.  
 
Although we found that most of the studies modelling these settings were in line with the 
conclusions from studies set in HIC for minimising deaths and cases, context may impact 
results, especially when very limited supply is considered. The studies based in LMIC 
settings assumed a higher level of vaccine supply available and level of coverage achieved 
than has been observed in most LMICs (see Table S5). Moreover, many LMICs have not yet 
established senior adult vaccination programmes, so targeting by age may be challenging and 
costly. Further research is urgently required to model  the effect of different levels of supply 
on prioritisation in lower income settings.  
 
There was only one study modelling inter- country allocation of vaccines, despite the political 
importance of this issue. [42] That one study found that doses should be allocated equally by 
population size if minimising deaths, and allocated preferentially to low- and middle-income 
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countries if minimising life years lost. Since this differs drastically from the current allocation 
of vaccine doses globally, it points to the need for further investigation and action. [9] 
 
Our review found that the optimal prioritisation strategy to pursue depends on the public 
health objective(s) of the decision-maker, with different conclusions depending on whether 
the objective is reducing cases or reducing mortality.  [31] [32] The trade-offs between 
different objectives are a challenging ethical issue for decision-makers.   
 
The WHO SAGE values framework for the allocation and prioritization of vaccines proposed 
6 principles as the ethical basis of decisions on vaccine prioritisation: the promotion of 
human well-being, equal respect, global equity, national equity, reciprocity and legitimacy. 
[2] Within the framework, reducing disease burden overall (and not purely the number of 
deaths) is a key consideration to promote human wellbeing. However, only one study 
considered integrated burden of disease outcomes such as QALYs that combine both 
morbidity and mortality in relation to prioritisation [11], one study considered DALYs. [19] 
This evidence gap may be particularly limiting in settings with a younger population, such as 
in many low- and middle-income countries, where overall mortality may be a smaller 
proportion of the overall COVID-19-related burden morbidity compared to high-income 
countries.  
 
Only one study considered within-country equity (such as prioritising populations that have 
suffered disproportionately from COVID-19 because of their socioeconomic status). [37] We 
also consider the few economic studies, such as economic evaluations, to represent a research 
gap. The choice of one vaccine strategy over another in the studies evaluated often only took 
into account the net health gain, yet the choice of the most appropriate vaccination strategy 
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should take into account health benefits, costs and the willingness to pay threshold - which 
varies in each setting. [43] 
 
Our findings are limited by several methodological issues. By limiting our search to English 
language studies, we may have missed relevant studies, particularly in low- and middle-
income countries. Furthermore, much of this literature is pre-print studies which are not peer-
reviewed, so the quality of the evidence presented here should be viewed with caution. 
Finally, to highlight key findings across all studies, we categorised the reviewed studies 
according to the broad public health objectives that they aimed to fulfil. However, this 
categorisation may have obscured some nuances within studies, such as where there were 




The findings of this systematic literature review have provided empirical evidence for the 
prioritisation of senior adults for vaccination to minimise COVID-19 deaths and young 
people to minimise COVID-19 transmission. However, there remain critical gaps in the 
evidence around strategies that reduce overall health outcomes, consider the costs of different 
prioritisation strategies and for low- and middle- income settings. The research gaps 
identified can help to guide the direction of further research on vaccination prioritisation as 
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Figure 1.  
 
WHO SAGE vaccine prioritisation recommendations under different supply scenarios during 
community transmission (adapted from the WHO sage roadmap for prioritizing uses of 
COVID-19 vaccines in the context of limited supply) 
 
 
Stage I (very limited vaccine availability, for 1–10% nat. pop.) 
 
1a: Health workers at high to very high risk of acquiring and transmitting infection.  
1b: Older adults 
 
 
Stage II (limited vaccine availability, for 11–20% nat. pop.) 
 
Older adults not covered in Stage I. 
  
Groups with comorbidities  
 
Sociodemographic groups at significantly higher risk of severe disease or death (depending 
on country context)  
 
Health workers engaged in immunization delivery (routine and COVID-19).  
 
High-priority teachers and school staff  
 
Stage III (moderate vaccine availability, for 21–50% nat. pop.) 
 
Remaining teachers and school staff.  
 
Other essential workers outside health and education sectors  
 
Pregnant women  
  
Health workers at low to moderate risk of acquiring and transmitting infection  
 
Personnel needed for vaccine production and other high-risk laboratory staff.  
 
Social/employment groups at elevated risk of acquiring and transmitting infection because 
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2279 records identified through 
search 
1820 records screened and 
assessed for eligibility 
 
1765 records excluded because: 
- COVID-19 vaccination not explicitly 
modelled  
- Modelled vaccination outcomes in the 
clinical setting 
- Duplicate of model 
- Model purely theoretical 55 full-text articles assessed for 
eligibility 
18 articles excluded after review of full text 
because:  
- Model does not address vaccination 
prioritisation  
36 articles included 
459 duplicates removed 
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HIC, MIC & LIC 2 
HIC & MIC 1 
HIC, UMIC, LMIC & LIC 1 
Theoretical 1 
Not clear 1 
Model features  
Deterministic, compartmental 23 
Stochastic, agent-based 5 
Stochastic, compartmental 4 
Deterministic, delay differential equation 1 
Linear 1 
Unclear 2 
Model structure  
SEIR 11 
Expanded SEIR 15 
Expanded SIR 5 
SAPHIRE 1 
Unclear natural history 4 
Contact matrix  
Age 19 
Age & essential worker status  1 
Age & day-specific 1 
Age & location 1 
Age, antibody status, major nationalities 1 
Occupation, age, location & intensity of interaction 1 
Social contact network 3 
Vulnerable, front-line workers, non-vulnerable 1 
Homogeneous mixing 2 
Geographic mapping and socio-economic status 1 
Jurisdiction contact rate (invariant with age) 1 
Unclear 4 




ICU admission 5 
No of vx to avert one infection 1 
Loss of economic benefits 1 
Years of life lost 3 
QALYs 2 
DALYs 1 
Cost-effectiveness ratio 1 
Net present value of damages (VSL & DALYs) 1 
Infection attack rate 1 
Peak infections 1 
Risk of new wave 1 
Life-years gained 1 
Total cost 2 
Net monetary benefits 1 
Effective reproductive number 1 
Herd immunity 1 
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1 Also includes:  [21] & [22] seniors and middle aged adults, [26] seniors and health workers, [25] seniors at full dose and young adults at 
quarter dose, [28] young adult and middle aged essential workers, [24] seniors & young and middle aged group in high contact with them, 
[23] high social contact group & seniors. Other: [34] school-going youth, [35] by serology testing, [30] non-vulnerable group. *Appears 
twice 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprintthis version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104doi: medRxiv preprint 
 
26 






































































 [31], [32] [32] [31], [32] [31], [32], 
[37] 






[14] [14] [27] [27] [28]* [14], [27], 
[28]* 














[18]  [18] [18]  [25]* 




2 Also includes young and middle-aged adults, young adults and children.  Other: [40] all age groups equally, [35] & [38] by 
serology testing, [39] area of low disease burden. *Appears twice 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprintthis version posted June 28, 2021. ; https://doi.org/10.1101/2021.06.21.21259104doi: medRxiv preprint 
